KME-0584

N/A

Report date: 2024/02/22 10:20:39

NME

Base Information

Drug NameKME-0584

Drug Alias NameKME-0584

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionInterleukin-1 receptor-associated kinase 1 inhibitorsInterleukin-1 receptor-associated kinase 4 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors

TargetsInterleukin-1 receptor-associated kinase 1Interleukin-1 receptor-associated kinase 4Tyrosine-protein kinase receptor FLT3

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCincinnati Children'S Hospital Medical Center National Center For Advancing Translational Sciences

China Registration ClassN/A

Develop Information

Active CompaniesKurome Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A